China's Shanghai Pharmaceuticals R&D spending 2019, by product
In 2019, Shanghai Pharmaceutical Group Co., Ltd. invested around 13.9 million yuan in researching and developing its Hydroxychloroquine sulfate tablets, the highest R&D spending among all other products. The enterprise is one of the largest national pharmaceutical groups in China which owns over 1,700 pharmacies.